California Lab Claims First Human Use of AI-Designed Virus to Fight Superbugs

Key points

• Radical Numerics, a California AI research lab, announced on Tuesday that it administered a custom AI-designed virus named Omnii-1 to a human patient.
• The treatment targeted an antibiotic-resistant bacterial infection under a physician-led compassionate-use pathway, as the patient had few remaining medical options.
• The company claims its AI model, trained on genomic sequences and phage-host interaction data, can rapidly design bacteriophages that specifically kill target bacteria while sparing beneficial gut microbes.
• The announcement is pending peer review, and the startup withheld specific clinical outcome data citing patient privacy, though it confirmed laboratory tests showed the phages eliminated the patient's bacteria.
• This development aims to address the projected 40 million deaths from antibiotic-resistant superbugs by 2050 by accelerating the timeline for finding effective treatments.

Background

Previous coverage from our archive indicates that Radical Numerics had already published a technical report regarding this treatment on October 22, 2026, but experts remained skeptical due to the lack of peer review and transparency. Earlier reports also noted that while laboratory tests confirmed the phages eliminated the patient's bacteria, the company withheld clinical outcome data to protect patient privacy, citing the lack of evidence from a single case.

Why it matters

If verified, this could be the first time AI-designed bacteriophages have been administered to a human patient, potentially offering a scalable solution to the growing threat of antibiotic-resistant superbugs, which are projected to cause nearly 40 million deaths by 2050.

What to watch

The treatment is pending scientific scrutiny in the form of a peer-reviewed study. Radical Numerics plans to continue characterizing the activity of its AI-designed phage variants against target hosts to inform subsequent rounds of modeling and design.